结节病患者的生长抑素受体闪烁扫描术和镓闪烁扫描术

Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis.

作者信息

Lebtahi R, Crestani B, Belmatoug N, Daou D, Genin R, Dombret M C, Palazzo E, Faraggi M, Aubier M, Le Guludec D

机构信息

Department of Nuclear Medicine, Hopital Bichat, Assistance Publique H pitaux de Paris, France.

出版信息

J Nucl Med. 2001 Jan;42(1):21-6.

PMID:11197973

Abstract

UNLABELLED

Somatostatin receptor scintigraphy (SRS) has been shown to reveal sarcoidosis sites. The aim of this study was to prospectively compare SRS and gallium scintigraphy in the evaluation of pulmonary and extrapulmonary involvement in patients with proven sarcoidosis.

METHODS

Eighteen patients with biopsy-proven sarcoidosis were included. Nine were or recently had been receiving steroid therapy at the time of the examination. Planar gallium scintigraphy (head, chest, abdomen, and pelvis) and thoracic SPECT were performed at 48-72 h after injection of a mean dose of 138 +/- 21 MBq 67Ga. Planar SRS and thoracic SPECT were performed at 4 and 24 h after injection of a mean dose of 148 +/- 17 MBq 111n-pentetreotide.

RESULTS

Gallium scintigraphy found abnormalities in 16 of 18 patients (89%) and detected 64 of 99 clinically involved sites (65%). SRS found abnormalities in 18 of 18 patients and detected 82 of 99 clinically involved sites (83%). Of the 9 treated patients, gallium scintigraphy found abnormalities in 7 (78%), detecting 23 of 39 clinically involved sites (59%), whereas SRS found abnormalities in 9, detecting 32 of 39 clinically involved sites (82%).

CONCLUSION

This study suggests that, compared with gallium scintigraphy, SRS appears to be accurate and contributes to a better evaluation of organ involvement in sarcoidosis patients, especially those treated with corticosteroids.

摘要

未标记

生长抑素受体闪烁扫描术（SRS）已被证明可显示结节病部位。本研究的目的是前瞻性比较SRS和镓闪烁扫描术在评估经证实患有结节病患者的肺部和肺外受累情况。

方法

纳入18例经活检证实为结节病的患者。其中9例在检查时正在接受或近期接受过类固醇治疗。在注射平均剂量为138±21MBq的67Ga后48 - 72小时进行平面镓闪烁扫描术（头部、胸部、腹部和骨盆）及胸部单光子发射计算机断层扫描（SPECT）。在注射平均剂量为148±17MBq的111铟 - 喷替肽后4小时和24小时进行平面SRS及胸部SPECT。

结果

镓闪烁扫描术在18例患者中的16例（89%）发现异常，在99个临床受累部位中检测到64个（65%）。SRS在18例患者中均发现异常，在99个临床受累部位中检测到82个（83%）。在9例接受治疗的患者中，镓闪烁扫描术在7例（78%）发现异常，在39个临床受累部位中检测到23个（59%），而SRS在9例中发现异常，在39个临床受累部位中检测到32个（82%）。